KN-62 enhances Chlamydia pneumoniae-induced p44/p42 mitogen-activated protein kinase activation in murine fibroblasts and attenuates in vitro infection

被引:6
作者
Haralambieva, I
Iankov, I
Mitev, V
Mitov, I
机构
[1] Med Univ, Dept Microbiol, Preclin Univ Ctr, Sofia 1431, Bulgaria
[2] Med Univ, Dept Chem & Biochem, Sofia, Bulgaria
关键词
fibroblasts; signal transduction; mitogen-activated protein kinase; KN-62; infectivity; Chlamydia pneumoniae;
D O I
10.1111/j.1574-6968.2002.tb11384.x
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Chlamydia pneumoniae elementary bodies were demonstrated to increase the proliferation of murine fibroblast cell line L-929 and rapidly activate p44/p42 mitogen-activated protein kinase (MAPK) in a protein kinase C. (PKC) and protein kinase A (PKA)-independent way. Ca2+/calmodulin-dependent protein kinase (CaM kinase) inhibitor KN-62 significantly enhanced C. pneumoniae-induced MAPK phosphorylation, suggesting negative control of CaM kinase pathway on the MAPK cascade. In in vitro infection assay, the upstream MAPK kinase 1/2 inhibitor U0126 increased 2.5-fold C. pneumoniae infectivity in L-929 cells, while KN-62 reduced the infection by 36%. Our findings provide insight into the molecular mechanisms of bacterium-host cell interactions and demonstrate the protective role of MAPK in murine fibroblasts, suggesting novel therapeutic approaches to the treatment and prevention of chlamydial infections. (C) 2002 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:149 / 155
页数:7
相关论文
共 32 条
[11]   ASSOCIATION OF CHLAMYDIA-PNEUMONIAE (STRAIN TWAR) INFECTION WITH WHEEZING, ASTHMATIC BRONCHITIS, AND ADULT-ONSET ASTHMA [J].
HAHN, DL ;
DODGE, RW ;
GOLUBJATNIKOV, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (02) :225-230
[12]   Cross-reaction between the genus-specific lipopolysaccharide antigen of Chlamydia spp. and the lipopolysaccharides of Porphyromonas gingivalis, Escherichia coli O119 and Salmonella newington:: Implications for diagnosis [J].
Haralambieva, I ;
Iankov, I ;
Petrov, D ;
Ivanova, R ;
Kamarinchev, B ;
Mitov, I .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2001, 41 (03) :99-106
[13]   Monoclonal antibody of IgG isotype against a cross-reactive lipopolysaccharide epitope of Chlamydia and Salmonella Re chemotype enhances infectivity in L-929 fibroblast cells [J].
Haralambieva, IH ;
Iankov, ID ;
Petrov, DP ;
Mladenov, IV ;
Mitov, IG .
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2002, 33 (02) :71-76
[14]   Involvement of intermediary metabolites in the pathway of extracellular Ca2+-induced mitogen-activated protein kinase activation in human fibroblasts [J].
Huang, SX ;
Maher, VM ;
McCormick, JJ .
CELLULAR SIGNALLING, 1999, 11 (04) :263-274
[15]   The effect of chemical blockade of PKC with Go6976 and Go6983 on proliferation and MAPK activity in IL-6-dependent plasmacytoma cells [J].
Iankov, I ;
Praskova, M ;
Kalenderova, S ;
Tencheva, Z ;
Mitov, I ;
Mitev, V .
LEUKEMIA RESEARCH, 2002, 26 (04) :363-368
[16]   Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen [J].
Jackson, LA ;
Campbell, LA ;
Kuo, CC ;
Rodriguez, DI ;
Lee, A ;
Grayston, JT .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (01) :292-295
[17]   Chlamydial virulence determinants in atherogenesis: The role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions [J].
Kalayoglu, MV ;
Indrawati ;
Morrison, RP ;
Morrison, SG ;
Yuan, Y ;
Byrne, GI .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 :S483-S489
[18]  
KAUPPINEN M, 1995, CLIN INFECT DIS, V21, P244
[19]   Cutting edge: Heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells [J].
Kol, A ;
Lichtman, AH ;
Finberg, RW ;
Libby, P ;
Kurt-Jones, EA .
JOURNAL OF IMMUNOLOGY, 2000, 164 (01) :13-17
[20]   Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages [J].
Kol, A ;
Bourcier, T ;
Lichtman, AH ;
Libby, P .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (04) :571-577